---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-017885"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:44:29.603595+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acumen raises $35.75M, reports positive EBD preclinical data with 14-40x brain penetration

## Summary
- Gross proceeds of $35.75M from private placement of 10,833,331 shares at $3.30/share; led by RA Capital.
- Preclinical data for EBD program: 14-40x brain levels in NHPs vs. native antibodies; low anemia risk.
- Subcutaneous dosing feasible; IND submission for lead candidate targeted for mid-2027.
- Proceeds primarily to support EBD program preclinical work and working capital.

## SEC filing metadata
- accession: 0001628280-26-017885
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000162828026017885/0001628280-26-017885-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000162828026017885/abos-20260313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-017885
- JSON: https://secwatch.observer/filing/0001628280-26-017885.json
- Plain text: https://secwatch.observer/filing/0001628280-26-017885.txt

## Key facts
- Material Agreements
  Acumen Pharmaceuticals, Inc. entered into Registration Rights Agreement with certain institutional accredited investors valued at registration for resale of the Shares pursuant to a registration statement to be filed with the SEC (effective 2026-03-13).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional accredited investors
  - Value: registration for resale of the Shares pursuant to a registration statement to be filed with the SEC
  - Effective: 2026-03-13
  source text: In connection with the Private Placement, the Company and the Investors entered into a Registration Rights Agreement, dated March 13, 2026 (the “ Registration Rights Agreement ”), providing for the registration for resale of the Shares pursuant to a registration statement (the “ Registration Statement ”) to be filed with the Securities and Exchange Commission (the “ SEC ”) no later than two business days after the date on which the Company files with the SEC its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000162828026017885/0001628280-26-017885-index.htm
- Material Agreements
  Acumen Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional accredited investors valued at 10,833,331 shares of common stock at $3.30 per share; expected gross proceeds ~$35.75 million (effective 2026-03-13).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional accredited investors
  - Value: 10,833,331 shares of common stock at $3.30 per share; expected gross proceeds ~$35.75 million
  - Effective: 2026-03-13
  source text: On March 13, 2026, Acumen Pharmaceuticals, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional accredited investors named therein (each, an “ Investor ” and collectively, the “ Investors ”), pursuant to which the Company agreed to sell to the Investors, in a private placement (the “ Private Placement ”), 10,833,331 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), at an offering price of $3.30 per Share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000162828026017885/0001628280-26-017885-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.